scholarly journals A CLINICAL STUDY OF SHILAJEET VATI IN PRAMEHA PURVARUPA (PRE-DIABETIC STATE)

2021 ◽  
Vol 9 (11) ◽  
pp. 2665-2670
Author(s):  
Esha Dhiman ◽  
Neetu Jha ◽  
Pradip Kumar Panda ◽  
Utkalini Nayak ◽  
Vinod Chandra Singh
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Plasma Glucose ◽  
Postprandial Glucose ◽  
Burning Sensation ◽  
Excessive Sweating ◽  
Average Percentage ◽  
Objective Parameter ◽  
Trial Drug ◽  
Paired T Test

Introduction- The incidence of Prameha is increasing rapidly because of changes in dietetic habits and lifestyle. If the Prameha Purvarupa (Pre-diabetic) clinical features are treated by formulation Shilajeet is recommended in Ayurvedic Classics, proven efficacious and widely practised in the management of Prameha (Diabetes). Materi- als and methods- 30 patients from OPD and IPD of Govt. Ayurvedic College & Hospital, Balangir, fulfilling the Subjective and Objective Parameters were registered for the clinical trial. After diagnosis, they were under trial with Ayurvedic formulation Shilajeet Vati treated in a dose of 2 Vati (500mg each) twice daily empty stomach, for a period of 30 days with Ushna Jala. The assessment of subjective and objective parameters was evaluated on the 10th, 20th and 30th day from the day of initiation of trial up to 30 days in order to find the efficacy of the trial by statistical paired ‘t’ test. Observation and results- The average percentage of improvement in subjective parame- ter Prabhuta Mutrata (quantity) 71.43%, Prabhuta Mutrata (frequency) 77.78%, Pipasa (increased thirst) 72.73%, Kshudha (excessive appetite) 72.22%, Kara-pada Daha (burning sensation in hand and feet) 73.81%,Kara-pada Suptata (numbness of hand and feet) 80%, Sweda Pravritti (excessive sweating) 83.33%, Mukha Sho- sha (dry mouth) 79.17%, Mukha Madhurya (sweetness in mouth) 77.78%, Sheeta Priyata (liking for cold things) 80% and Madhura Shukla Mutrata (sweetness in urine) 100% and in objective Parameter fasting plasma glucose 68.89%, postprandial glucose 81.11%, HbA1c 73.33%. It has been observed that the trial drug patients are highly significant (p<0.001) to reduce both Subjective and Objective parameters after 30 days of treatment. Discussion and Conclusion- Prameha is a Kapha Pradhana Tridoshaja Vyadhi in which Meda is a Pradhana Dushya. The drug showed a potent Pramehahar effect which is evident from the reduction in the Subjective Parameter of Prameha and objective parameter of the levels of FBS, PPBS and HbA1c in patients. No side effect was noticed during the clinical study of Shilajeet Vati. Keywords: Prameha, Diabetes, Shilajeet Vati.

scholarly journals Study the Efficacy of Rodhradigana Vasti in the Management of Sthaulya (Overweight)

2021 ◽  
pp. 158-166
Author(s):  
Shweta Parwe ◽  
Poonam Ashtankar ◽  
Piyush Bhagwat ◽  
Milind Nisargandha
Keyword(s):  
Statistical Analysis ◽  
Clinical Study ◽  
Lipid Profile ◽  
Study Design ◽  
Eating Habits ◽  
Positive Finding ◽  
New Era ◽  
Modern Period ◽  
Objective Parameter ◽  
Paired T Test

Background: Obesity (Sthaulya) has been one of the primary diseases of the modern period, with its changing lifestyles, climate, and eating habits. Everyone has become a victim of many diseases caused by poor eating habits, and obesity is just one of them. Obesity is the privilege of the new era of robots and materialistic devices. In 2008, the WHO assessed that 1.5 billion individuals, were overweight and more than 200 million men and almost 300 million women were fat. Objectives: To evaluate the effect of Rodhradigana Vasti in Sthaulya. Study Design: This was an open-labelled single-arm interventional clinical study. Methods: 15 patients of Sthaulya were registered from Panchakarma, and Rodhradigana Vasti was administered for 15 days. Statistical Analysis: The data were statistically analyzed using the Wilcoxon Signed Ranks Test for Subjective Parameter and paired t-test for Objective Parameter. Results: In this study, decreased weight, lipid profile and subjective parameters show positive finding after the intervention of Vasti. Conclusion: Rodhradigana Vasti is one of the best remedies for relieving Sthaulya.

Herpes Zoster Treatments: Results of a Clinical Trial Relative to the Use of Rifamycin SV versus Neuramide

1984 ◽  
Vol 12 (4) ◽  
pp. 255-260 ◽  
Author(s):  
L Bruni ◽  
G Tagliapietra ◽  
P Innocenti
Keyword(s):  
Clinical Trial ◽  
Herpes Zoster ◽  
Clinical Study ◽  
Statistical Tests ◽  
Burning Sensation ◽  
Rifamycin Sv ◽  
Controlled Clinical Study

The authors describe a controlled clinical study in which rifamycin SV 250 mg intramuscularly and topical b.i.d. was compared to intramuscular neuramide b.i.d. plus, where necessary, other drugs (antibiotics, polivitamins, analgesics, etc.) for the treatment of two groups of thirty randomly selected patients suffering from herpes zoster. In all patients the symptoms were controlled by both treatments but statistical tests revealed that rifamycin SV was able to heal pain (p < 0·05), vesicles, crusts and burning sensation (p < 0·1) faster than neuramide. Furthermore, by the seventh day of therapy, the authors found that rifamycin SV reduced the intensity of both pain and erythema (p < 0·01 for pain; p < 0·05 for erythema) more than neuramide.

Comparative Clinical study of Jatyadi Taila and Jatyadi Ghrita in the management of Dushta Vrana

2018 ◽  
Vol 3 (3) ◽  
Author(s):  
Rajendra Joshi ◽  
N. B. Mashetti ◽  
Rakesh Kumar Gujar
Keyword(s):  
Clinical Study ◽  
Burning Sensation ◽  
Normal Process ◽  
Surgical Practice ◽  
Local Factors ◽  
Significant Difference ◽  
Comparative Clinical Study ◽  
Group A ◽  
Contaminated Wound ◽  
Group B

Dushta Vrana is a common and frequently encountered problem faced in surgical practice. The presence of Dushta Vrana worsens the condition of the patient with different complications and may become fatal. Local factors on wound like slough, infection and foreign body, affect the normal process of healing. A healthy wound in a normal body heals earlier with a minimum scar as compared to a contaminated wound. Therefore in this study all the efforts are made to make a Dushta Vrana into a Shuddha Vrana. Once the Vrana becomes Shuddha, Ropana of the Vrana will start. The objective of the study was to evaluate the clinical efficacy of Jatyadi Taila and Jatyadi Ghrita in Dushta Vrana. Clinically diagnosed 60 Patients of Dushta Vrana were randomly divided into two groups, each consisting of 30 Patients. Group A were treated with the Jatyadi Taila and Group B was treated by Jatyadi Ghrita. The results observed was based on the relief obtained on the subjective and objective parameters taken for consideration for this study viz, size of ulcer, discharge, smell, pain, burning sensation, itching and granulation were found significant (P Lass Than 0.05). On the basis of assessment criteria and overall result of treatment, the patients of Jatyadi Taila group showed better results when compared to Jatyadi Ghrita group. Even though statistically there is no much significant difference between the two groups, but by seeing the effect on individual parameters (subjective and objective) and over all response, Jatyadi Taila seems to be effective when compared to Jatyadi Ghrita. It is having more Ropana qualities when compared to Shodhana.

scholarly journals Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Asger S. Paludan-Müller ◽  
Perrine Créquit ◽  
Isabelle Boutron
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Clinical Study ◽  
Primary Source ◽  
European Medicines Agency ◽  
Clinical Trial Registries ◽  
Number Of Patients ◽  
Journal Publications ◽  
Clinical Study Reports ◽  
Completeness Of Reporting

Abstract Background An accurate and comprehensive assessment of harms is a fundamental part of an accurate weighing of benefits and harms of an intervention when making treatment decisions; however, harms are known to be underreported in journal publications. Therefore, we sought to compare the completeness of reporting of harm data, discrepancies in harm data reported, and the delay to access results of oncological clinical trials between three sources: clinical study reports (CSRs), clinical trial registries and journal publications. Methods We used the EMA clinical data website to identify all trials submitted to the EMA between 2015 and 2018. We retrieved all CSRs and included all phase II, II/III or III randomised controlled trials (RCTs) assessing targeted therapy and immunotherapy for cancer. We then identified related records in clinical trial registries and journals. We extracted harms data for eight pre-specified variables and determined the completeness of reporting of harm data in each of the three sources. Results We identified 42 RCTs evaluating 13 different drugs. Results were available on the EMA website in CSRs for 37 (88%) RCTs, ClinicalTrials.gov for 36 (86%), the European Clinical Trials Register (EUCTR) for 20 (48%) and in journal publications for 32 (76%). Harms reporting was more complete in CSRs than other sources. We identified marked discrepancies in harms data between sources, e.g. the number of patients discontinuing due to adverse events differed in CSRs and clinical trial registers for 88% of trials with data in both sources. For CSRs and publications, the corresponding number was 90%. The median (interquartile range) delay between the primary trial completion date and access to results was 4.34 (3.09–7.22) years for CSRs, 2.94 (1.16–4.52) years for ClinicalTrials.gov, 5.39 (4.18–7.33) years for EUCTR and 2.15 (0.64–5.04) years for publications. Conclusions Harms of recently approved oncological drugs were reported more frequently and in more detail in CSRs than in trial registries and journal publications. Systematic reviews seeking to address harms of oncological treatments should ideally use CSRs as the primary source of data; however, due to problems with access, this is currently not feasible.

Effect of Ark malahara in Vicharchika- A clinical study

2020 ◽  
Vol 6 (2) ◽  
pp. 50-54
Author(s):  
Suman Purohit ◽  
◽  
Shweta Shukla ◽  
Khemchand Sharma ◽  
◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Medical Practice ◽  
Satisfactory Treatment ◽  
Clinical Presentations

Vicharchika (Eczema) is a type of kshudrakustha characterized with symptoms, namely, kandu, Srava, Pidaka and Shyavata and Pidikotpatti. Vicharchika is often correlated to eczema based on the clinical presentations. No satisfactory treatment is available in contemporary medical practice. In Ayurveda variousformulations are mentioned for treatment of Vicharchika. In the present study a clinical trial was done using Ark Malahara in 15 patients of either sex in between the age of 20 to 70 years. Highly significant result is obtained in Kandu, while significant result was obtained in Daha, Srava, Pidika, Rukshta, Vaivarnya.

scholarly journals Infra-Zygomatic Mini Screws Compared to High Pull Headgear for Distalization And Intrusion of Maxillary Molars in Growing Patients with Class II Malocclusion: A Randomized Clinical Trial

2021 ◽  
Vol 2 (1) ◽  
pp. 14-19
Author(s):  
Ahmed K. Afify ◽  
Amr E. El-Dakroury ◽  
Sherif A. El-Kordy ◽  
Mostafa M. El-Dawlatly
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Treatment Duration ◽  
Class Ii ◽  
Class Ii Malocclusion ◽  
Maxillary Molars ◽  
Randomized Clinical Study ◽  
Molar Intrusion ◽  
Before And After ◽  
Patient Cooperation

Objective: The aim of the present randomized clinical study was to evaluate the distalization and intrusion effect of an Infra-zygomatic mini-screws supported appliance and compare it with high pull headgear appliance in treatment of growing patients with class II malocclusion. Methodology: 22 growing boys aged between (10 to 12 years) with class II div 1 malocclusion randomly divided to 2 equal groups. The first group treated with high pull headgear with acrylic splint and the second one treated with an Infra-zygomatic mini-screws supported appliance. The treatment duration was 8 months for both groups. Lateral cephalometric radiographs were taken before and after the treatment for each patient to be analyzed. Results: The maxillary first molar distalization was 2.58±2.31 mm in head gear group and 1.53±2.83 mm in mini-screws group. There was no significant maxillary first molar intrusion in both groups. There were no significant differences between the two groups. Conclusions: the mini-screws supported appliance can be used as the fixed replacement of the removable high pull headgear appliance with no need for patient cooperation.

scholarly journals A CLINICAL STUDY ON THE ROLE OF ERANDA KSHARA IN STHAULYA (OBESITY)

2015 ◽  
Author(s):  
*Borse Vilas Pundlikrao ◽  
Bhaskare Sunil A ◽  
Pawar Kiran Bhikaji ◽  
Meshram Dnyaneshwar Sudhakar
Keyword(s):  
Clinical Study ◽  
Waist Circumference ◽  
Duration Of Treatment ◽  
Average Percentage ◽  
Waist Hip Ratio ◽  
Arm Circumference ◽  
Laboratory Investigations ◽  
Basic Concepts

There are so many basic concepts in Ayurveda; Dhatvagni mandya is one of them. The whole phenomenon of disease cannot be completed without Dosha-Dushya Siddhant. They play important role in the pathology of disease. Obesity is one of them, which affect the health as well as life span. Sthaulya is one of the disease which is known to mankind since Vedic era, has been dealt in great details in Ayurvedic texts. The sign, symptoms and etiological factor of Sthaulya show very much resemblance with obesity. Worldwide Obesity is emerging health problem. It is a metabolic disorder which has affected every corner of world. In present study 30 patients of Sthaulya were selected from OPD and IPD of M.A. Podar hospital, Mumbai. These patients were undergone throw laboratory investigations. They were treated with Eranda Kshara with Ghrita bharjit Hingu given orally, duration of treatment was two months and follow up was done with parameters like Height, weight, BMI, Mid arm circumference, Waist circumference, Waist Hip ratio and symptoms of Sthaulya. It was observed that Atikshuda and Atitrushna reduce significantly. It shows relief in weight, BMI, Waist Circumference, Mid Arm Circumference and Waist Hip ratio. There was no significant change in hematological as well as Urine investigations. Average percentage of relief was 60.72%. 

scholarly journals Advances in recent patent and clinical trial drug development for Alzheimer’s disease

2014 ◽  
Vol 3 (4) ◽  
pp. 429-447 ◽  
Author(s):  
Haibin Liu ◽  
Lirong Wang ◽  
Weiwei Su ◽  
Xiang-Qun Xie
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Drug Development ◽  
Trial Drug

Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: An open-label, single-center, single-arm clinical study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16117-e16117
Author(s):  
Jian-Xu Li ◽  
Ting-Shi Su ◽  
Xiao-Feng Lin ◽  
Yi-Tian Chen ◽  
Shi-Xiong Liang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trial ◽  
Radiation Therapy ◽  
Clinical Study ◽  
Cancer Staging ◽  
Advanced Hepatocellular Carcinoma ◽  
Single Center ◽  
Open Label ◽  
Grade 3 ◽  
Clinical Trial Information

e16117 Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: an open-label, single-center, single-arm clinical study Jian-Xu Li, Ting-Shi Su, Xiao-Feng Lin, Yi-Tian Chen, Shi-Xiong Liang, Bang-De Xiang; Guangxi Medical University Cancer Hospital, Nanning, China Abstract Research Funding: Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China. Guangxi Medical and Health Appropriate Technology Development and Application Project (No. S2019039), Guangxi, China. Background: Based on the results of recent studies, the PD-1 monoclonal antibodies have been approved to treat the patients with advanced hepatocellular carcinoma (HCC) by the FDA. Radiation therapy (RT) can enhance responsiveness to PD-1 monoclonal antibody by potential mechanisms. A phase Ⅱa study was conducted to assess the safety and the efficacy of combining RT with anti-PD-1 for patients with advanced hepatocellular carcinoma. Methods: Patients with advanced HCC were eligible. Stereotactic body radiation therapy (SBRT) were adopted, and the dose of radiation were Dt-PGTV 30-50 Gy/10fractions. Camrelizumab (200mg) were given intravenously every 3 weeks since the first day of RT until disease progression, or intolerable toxicity. Adverse events (AEs) and objective response rate (ORR) were summarized to assess the safety and efficacy. Results: From April 2020 to November 2020, 17 patients were enrolled (median age 54, range 32-69). 15 (88%) patients were male. 14 (82%) had ECOG performance score of 0. All the patients had Child-Pugh score A. 16 patients staged as Barcelona Clinic Liver Cancer staging C or China Liver Cancer staging Ⅲ. Extrahepatic metastases were identified in 11 (65%) patients. 13 (77%) patients were Hepatitis B virus infected. 15 (88%) patients had previously 2 lines or more chemotherapy. 9 (53%) patients had Alpha-fetoprotein level≥400 ng/ml. The ORR was 47%. The best response assessed by RECIST 1.1 was partial response (8 patients). Four patients had grade 3 immune-related adverse events (irAEs), including increased aspartate aminotransferase and alanine transaminase (n =1)，decreased hemoglobin (n =1)，decreased platelet count (n =1)，decreased neutrophil count (n =1). All grade 3 irAEs were mitigated with proper treatment. None treatment-related deaths occurred. Conclusions: In this study, RT combined with anti-PD-1 had an acceptable safety profile and indicated an effective treatment option in patients with unresectable HCC. Clinical trial information: NCT04193696. Clinical trial information: NCT04193696.

Sign in / Sign up

Export Citation Format

Share Document